There are currently 119 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
NCT04368039
Recruiting
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Gender:
All
Ages:
Between 15 years and 35 years
Trial Updated:
07/31/2023
Locations: Harding Hospital, Columbus, Ohio
Conditions: Psychosis, Schizophrenia, First-episode Psychosis
Register for Updates
CAE for Poorly Adherent Individuals With Schizophrenia
NCT06061952
Recruiting
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Schizophrenia
Register for Updates
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981
Recruiting
Background: Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function. People with schizophrenia have difficulty thinking and experience hallucinations and delusions. Medications that change brain dopamine receptors can decrease these hallucinations and delusions. The cause of schizophrenia and its association with brain dopamine receptors is not known but may be clarified by studying dopamine receptors in people w... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/24/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizoaffective Disorder, Schizophrenia
Register for Updates
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
NCT00001246
Recruiting
Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the name implies, magnetism to create pictures with excellent anatomical resolution. Functional MRIs are diagnostic tests that allow doctors to not only view anatomy, but physiology and function. It is for these reasons that MRIs are excellent methods for studying the brain. In this study, researchers will use MRI to assess brain anatomy and function in X and Y chromosome variation... Read More
Gender:
All
Ages:
3 years and above
Trial Updated:
04/23/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder
Register for Updates
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064
Recruiting
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/23/2024
Locations: Alkermes Investigator Site, Dothan, Alabama +43 locations
Conditions: Schizophrenia, Bipolar I Disorder
Register for Updates
Deep rTMS Modulating Insula Synaptic Density and Smoking Behavior in Schizophrenia
NCT05724810
Recruiting
Purpose of the study: Evaluate the effect of deep repetitive transcranial magnetic stimulation (deep rTMS; hereafter abbreviated as "dTMS") on synaptic density measured with positron emission tomography (PET) and the radiotracer [11C]UCB-J. The investigators also seek to link plasticity changes in the regions targeted by the electric field (especially, the insula) to changes in the functioning of insula circuits and behavioral cigarette usage in patients with schizophrenia (SCZ). Importance of... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/23/2024
Locations: Stony Brook University, Stony Brook, New York
Conditions: Schizophrenia, Smoking Cessation, Tobacco Use
Register for Updates
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
NCT06315283
Recruiting
The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia. Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with ora... Read More
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
04/19/2024
Locations: Teva Investigational Site 15739, Los Alamitos, California +5 locations
Conditions: Schizophrenia
Register for Updates
Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?
NCT05268809
Recruiting
Wide ranging cognitive deficits are major drivers of functional decline and poor outcomes in people with schizophrenia (SZ) and bipolar disorder (BD). Medications do not target pathophysiological mechanisms thought to underlie these deficits. In the search for interventions targeting underlying cognitive impairment in SZ and BD, we look comprehensively beyond just the brain and to the potential role of dysfunctional systemic metabolism. Disrupted insulin and glucose metabolism are seen in medic... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/19/2024
Locations: San Francisco VA Medical Center, San Francisco, California
Conditions: Schizophrenia, Bipolar Disorder
Register for Updates
Inpatient Evaluation of Adults With Schizophrenia
NCT00001247
Recruiting
The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness. Schizophrenia and related psychoses are chronic brain disorders whose prognosis is often poor and whose pathophysiology remains obscure. Brain imaging technologies such s positron emission tomography (PET), functional magnetic resonance imaging (fMRI), and magnetic resonance imaging (MRI)... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia
Register for Updates
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
NCT00004571
Recruiting
The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. Schizophrenia is a brain disorder that results from subtle changes and abnormalities in neurons. These deficits likely occur in localized regions of the brain and may result in widespread, devastating consequences. The neuronal abnormalities are inherited through a complex combination of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Normal Physiology
Register for Updates
PET Scanning in Parkinson s Disease
NCT00024622
Recruiting
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-[F-18] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/16/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Schizophrenia, Parkinson's Disease
Register for Updates
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
NCT05211947
Recruiting
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visi... Read More
Gender:
All
Ages:
Between 18 years and 51 years
Trial Updated:
04/15/2024
Locations: Advanced Research Center, Inc., Anaheim, California +230 locations
Conditions: Schizophrenia
Register for Updates